Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Yahoo Finance12d
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc ...
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA
Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...
ETF Daily News11d
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com
In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17 ...
ETF Daily News9d
HC Wainwright Reiterates “Buy” Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The stock has a market cap of $264.14 million, a P/E ratio of -16.18 and a beta of 0.77.
Investing11d
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
WASHINGTON, DC – Today, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62% ...
The Business Journals12d
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
The company is fighting to protect its intellectual property from generic competition and get more drugs to market. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has started the year facing a new wave ...
Morningstar11d
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis is a serious digestive ...
Finanznachrichten11d
Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis is a serious digestive ...
Investing11d
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
WASHINGTON, DC – Today, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed ...
Nasdaq11d
Vanda Agrees To FDA's Offer Of Hearing On NDA For Gastroparesis Drug Candidate Tradipitant
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical company announced on Monday, that it has accepted the FDA's offer for a hearing regarding its New Drug Application or NDA for ...
Benzinga.com10d
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
Stay informed and make well-judged decisions with the assistance of our Ratings Table. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of ...